CSPC Pharmaceutical Group's (HKG:1093) phase III trial of Becotatug in combination with osimertinib met its primary endpoint at a pre-specified interim analysis and achieved positive topline results.
The drug combination was being tested for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Compared with platinum-based chemotherapy in combination with pemetrexed, the treatment combination significantly prolonged the progression-free survival of patients and showed a trend of benefit in overall survival.